Evidence map›Paper›PMID 35350323›Full record

ArticleACS omega2022

Hispolon-Loaded Liquid Crystalline Nanoparticles: Development, Stability, In Vitro Delivery Profile, and Assessment of Hepatoprotective Activity in Hepatocellular Carcinoma.

Mohammad Javed Ansari, Mahfoozur Rahman, Khalid S Alharbi, Waleed M Altowayan, Ahmed Mahmoud Abdelhaleem Ali, Waleed H Almalki, Md Abul Barkat, Tanuja Singh, Shehla Nasar, Md Habban Akhter and 2 more

Open access · goldAbstract read
In one paragraph

Article in ACS omega, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 12 institutions in 2 countries.

Mohammad Javed AnsariDepartment of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-kharj 16278, Saudi Arabia.
Mahfoozur RahmanDepartment of Pharmaceutical Sciences, Shalom Institute of Health & Allied Sciences, Sam Higginbottom University of Agriculture, Technology & Sciences, Allahabad 211007, India.
Khalid S AlharbiDepartment of Pharmacology, College of Pharmacy, Jouf University, Sakakah 72388, Saudi Arabia.
Waleed M AltowayanDepartment of Pharmacy Practice, College of Pharmacy, Qassim University, Qassim 52571, Qassim, Saudi Arabia.
Ahmed Mahmoud Abdelhaleem AliDepartment of Pharmaceutics and Industrial Pharmacy, College of Pharmacy, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia.
Waleed H AlmalkiDepartment of Pharmacology and Toxicology, College of Pharmacy, Umm Al-qura University, Makkah 24382, Saudi Arabia.
Md Abul BarkatDepartment of Pharmaceutics, College of Pharmacy, University of Hafr Al Batin, Hafar Al Batin 39524, Saudi Arabia.
Tanuja SinghDepartment of Botany, Patliputra University, Patna 800020, Bihar, India.
Shehla NasarDepartment of Pharmacognosy, Faculty of Pharmacy, King Khalid University, Abha 62529, Saudi Arabia.
Md Habban AkhterSchool of Pharmaceutical and Population Health Informatics (SoPPHI), DIT University, Dehradun 248009, India.
Sarwar BegDepartment of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.ORCID https://orcid.org/0000-0002-3304-2712
Hani ChoudhryDepartment of Biochemistry, Cancer Metabolism & Epigenetic Unit, Faculty of Science, King Fahd Center for Medical Research, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
Dehradun Institute of Technology University · INJamia Hamdard · INJouf University · SAKing Abdulaziz University · SAKing Khalid University · SAPatliputra University · INPrince Sattam Bin Abdulaziz University · SAQassim University · SASam Higginbottom Institute of Agriculture · INTaif University · SAUmm al-Qura University · SAUniversity of Hafr Al-Batin · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present work describes the development and characterization of liquid crystalline nanoparticles of hispolon (HP-LCNPs) for treating hepatocellular carcinoma. HP-LCNPs were prepared by a top-down method utilizing GMO as the lipid and Pluronic F-127 as the polymeric stabilizer. The prepared formulations (HP1-HP8) were tested for long-term stability, where HP5 showed good stability with a particle size of 172.5 ± 0.3 nm, a polydispersity index (PDI) of 0.38 ± 0.31 nm, a zeta potential of -10.12 mV ± 0.05, an entrapment efficiency of 86.81 ± 2.5%, and a drug loading capacity of 12.51 ± 1.12%. Optical photomicrography and transmission electron microscopy images demonstrated a consistent, low degree of aggregation and a spherical shape of LCNPs. The effect of temperature and pH on the optimized formulation (HP5) indicated good stability at 45 °C and at pH between 2 and 5. In vitro gastrointestinal stability indicated no significant change in the particle size, PDI, and entrapment efficiency of the drug. The drug release study exhibited a biphasic pattern in simulated gastric fluid (pH 1.2) for 2 h and simulated intestinal fluid (pH 7.4) for up to 24 h, while the best fitting of the profile was observed with the Higuchi model, indicating the Fickian diffusion mechanism. The in vivo pharmacokinetic study demonstrated nearly 4.8-fold higher bioavailability from HP5 (AUC: 1774.3 ± 0.41 μg* h/mL) than from the HP suspension (AUC: 369.11 ± 0.11 μg* h/mL). The anticancer activity evaluation revealed a significant improvement in antioxidant parameters and serum hepatic biomarkers (SGOT, SGPT, ALP, total bilirubin, and GGT) in the diethyl nitrosamine-treated group of rats with the optimized LCNP formulation (HP5) vis-à-vis HP suspension.

Identifiers

PMID35350323
PMCPMC8945187
OpenAlexW4220877541

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.